Search - tctmd.com

Displaying 521 - 540 of 892

Sort: Relevancy | Date

News Conference News AHA 2018

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Michael O'Riordan

November 10, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Daily News

Long-term Risk Factor Control Linked to Survival in COURAGE Substudy

Yael L. Maxwell

October 30, 2018

News Daily News

Patients With Schizophrenia Reap Gains From CV Meds After MI

Todd Neale

October 24, 2018

News Daily News

Plaque Characteristics on OCT Offer Clues About Atherosclerotic Causes of MINOCA

Caitlin E. Cox

October 23, 2018

News Daily News

SURTAVI Stroke Analysis Published, Confirms Less Early Stroke With TAVR

Todd Neale

October 22, 2018

News Daily News

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Michael O'Riordan

October 15, 2018

News Daily News

Gender Gap May Be Narrowing in ACS Patients, With Mortality Advantage for Elderly Women

L.A. McKeown

October 12, 2018

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

Todd Neale

October 12, 2018

News Daily News

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

Michael O'Riordan

October 08, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2018

Shelley Wood

October 02, 2018

News Daily News

Prescription Omega-3 Fatty Acids Cut Cardiovascular Events: REDUCE-IT

Shelley Wood

September 24, 2018

Presentation TCT 2018

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Presenter: Deepak L. Bhatt, Tullio Palmerini, Michael Maeng

September 23, 2018

News Daily News

Aspirin Falters Yet Again in Primary Prevention: ASPREE

Michael O'Riordan

September 17, 2018

News Conference News ESC 2018

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

Shelley Wood

September 14, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

Caitlin E. Cox

September 04, 2018

News Conference News ESC 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Michael O'Riordan

August 26, 2018

News Conference News ESC 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

Shelley Wood

August 26, 2018

News Conference News ESC 2018

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

Shelley Wood

August 25, 2018

News Conference News ESC 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

Shelley Wood

August 20, 2018

Advertisement

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Long-term Risk Factor Control Linked to Survival in COURAGE Substudy

Patients With Schizophrenia Reap Gains From CV Meds After MI

Plaque Characteristics on OCT Offer Clues About Atherosclerotic Causes of MINOCA

SURTAVI Stroke Analysis Published, Confirms Less Early Stroke With TAVR

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Gender Gap May Be Narrowing in ACS Patients, With Mortality Advantage for Elderly Women

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

TCTMD’s Top 10 Most Popular Stories for September 2018

Prescription Omega-3 Fatty Acids Cut Cardiovascular Events: REDUCE-IT

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Aspirin Falters Yet Again in Primary Prevention: ASPREE

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

TCTMD’s Top 10 Most Popular Stories for August 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content